Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common heart drug shield breast cancer patients from Surgery-Related heart damage?

NCT ID NCT07583134

Disease control Sponsor: Chang-Ik Yoon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug propranolol can prevent heart injury after breast cancer surgery in women who also have high blood pressure or angina. One hundred participants will either receive propranolol before surgery or standard care. Researchers will measure heart stress using blood tests and examine tumor samples.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
propranolol (a beta-blocker drug)
What this could lead to
If it works, this could point toward a simple way to protect the heart during breast cancer surgery for patients with high blood pressure or chest pain.
What could go wrong
This is a small, early-phase trial with only 100 people. It may not show a clear benefit, and propranolol can cause side effects like low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients aged 20 to 70 years. 2. Patients diagnosed with hypertension or angina who require medication. 3. Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III. 4. ECOG performance status of 0-1. 5. Patients scheduled to receive standard postoperative treatment (including adjuvant radiotherapy 6. Patients who voluntarily decide to participate and sign the written informed consent form Exclusion Criteria: 1. Patients with distant metastases. 2. Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris. 3. Patients with clinically significant hepatic, hematologic, or renal dysfunction, defined as any of the following: ① ANC \<1,500/mm3 * Platelets \<100,000/mm3 * Hb \<9 g/dL * AST and ALT \> 2.5 x upper limit of normal (ULN) ⑤ Alkaline phosphatase \> 2.5 x ULN ⑥ Total bilirubin \> 1 x ULN ⑦ Serum creatinine \>1.5 x ULN or estimated creatinine clearance \< 60 mL/min (as calculated using the method standard for the institution) 4. Patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD). 5. Patients who are pregnant or breastfeeding at the time of enrollment. 6. Patients with a history of malignancy within the past 5 years. 7. Patients for whom data collection is considered difficult at the discretion of the investigator. 8. Patients who are unable to understand or complete study questionnaires. 9. Patients who have received β-blockers within 30 days prior to screening. 10. Patients with systolic blood pressure \< 100 mmHg or heart rate \< 55 beats per minute.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hypertensive disorder intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Myocardial injury after noncardiac surgery (MINS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Seoul St. Mary's Hospital, The Catholic University of Korea

    Seoul, Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.